Navigation Links
Discovery could help to develop drugs for organ transplant and cancer patients
Date:4/13/2012

MAYWOOD, Ill. -- Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.

The study is published online ahead of print in the Journal of Immunology. Senior author is Makio Iwashima, PhD, an associate professor in the Department of Microbiology & Immunology of Loyola University Chicago Stritch School of Medicine. Co-authors are Robert Love, MD, a professor in the Departments of Thoracic & Cardiovascular Surgery and Microbiology & Immunology and one of the world's leading lung transplant surgeons, and first author Mariko Takami, PhD, of the Department of Microbiology & Immunology.

The immune system relies on a balancing act between two types of cells. Effector cells attack tumor cells and cells infected by viruses or bacteria. Regulatory cells suppress the immune system so that it does not attack healthy tissue. If effector cells are too active, an individual can suffer autoimmune disorders such as lupus, Type 1 diabetes and multiple sclerosis. But if regulatory cells are too active, the immune system will not be aggressive enough to protect the individual from germs and cancer.

The study involved an immune system molecule called transforming growth factor beta (TGF-β). TGF-β is known to be a powerful regulator of the immune response -- generally suppressing the strength of the response. In this study, however, Loyola researchers demonstrated that TGF-β can amplify the immune response and result in a more effective targeted response under specific conditions.

"TGF-β is a double-edged sword," Iwashima said. "It augments immune system reactions but does not determine what direction they will take. Depending on conditions, these reactions can either activate or suppress the immune system."

The study involved mouse cells grown ex vivo in laboratory dishes. The next steps will be to study TGF-β in human cells and in animal models. Understanding the dual role of TGF-β could help in the development of drugs to either activate or suppress the immune system, as needed, Iwashima said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. New discovery of proteins involved in positioning muscular nuclei
4. Cell signaling discovery provides new hope for blood disorders
5. Gene mutation discovery sparks hope for effective endometriosis screening
6. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
7. Discovery of new vaccine approach for treatment of cancer
8. Zebrafish may help speed drug discovery
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Journal names discovery that HIV treatment can prevent spread breakthrough of the year
11. Salk discovery may lead to safer treatments for asthma, allergies and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... ... 22, 2017 , ... Social media marketing is transitioning from a singular person ... & Jones’ delves into this insight and more in its latest episode of its ... Vener meets up with social media strategist and partner of the digital firm Med|Ed ...
(Date:2/22/2017)... ... 22, 2017 , ... In today’s world, homeowners face a ... market, it is easy to start feeling frustrated and confused. To help Dallas ... security consultation. , Home Security Hardware Choices, There are innumerable choices for home ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading global ... management, today announced that Keppel Corporation has selected Apptricity Travel and Expense Management ... “We are excited to announce the partnership between Keppel and Apptricity for our ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Oncternal Therapeutics, Inc., a ... rare and common malignancies, today announced the closing ... company intends to use the proceeds to further ... to advance preclinical development of a new ROR1-targeted ... a first-in-class anti-ROR1 monoclonal antibody being developed to ...
(Date:2/22/2017)...  CVS Pharmacy is the first national retail pharmacy ... (PHO), the primary source of artificial trans fats in ... products. The retailer now offers over 600 exclusive snack ... fats. This comes a year and a half ahead of ... for processed foods to be reformulated without artificial trans ...
(Date:2/22/2017)... 2017 Des scanners sur smartphone destinés aux professionnels ... Europe , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , une société de santé ... au Canada , a annoncé aujourd,hui qu,elle a reçu ... fil Clarius C3 et L7, destinés à être utilisés par des professionnels ...
Breaking Medicine Technology: